Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 - Data from the national prostate cancer register in Sweden

Research output: Contribution to journalArticle

Standard

Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 - Data from the national prostate cancer register in Sweden. / Adolfsson, Jan; Garmo, Hans; Varenhorst, Eberhard; Ahlgren, Göran; Ahlstrand, Christer; Andren, Ove; Bill-Axelson, Anna; Bratt, Ola; Damber, Jan-Erik; Hellstrom, Karin; Hellstrom, Magnus; Holmberg, Erik; Holmberg, Lars; Hugosson, Jonas; Johansson, Jan-Erik; Petterson, Bill; Tornblom, Magnus; Widmark, Anders; Stattin, Par.

In: Scandinavian Journal of Urology and Nephrology, Vol. 41, No. 6, 2007, p. 456-477.

Research output: Contribution to journalArticle

Harvard

Adolfsson, J, Garmo, H, Varenhorst, E, Ahlgren, G, Ahlstrand, C, Andren, O, Bill-Axelson, A, Bratt, O, Damber, J-E, Hellstrom, K, Hellstrom, M, Holmberg, E, Holmberg, L, Hugosson, J, Johansson, J-E, Petterson, B, Tornblom, M, Widmark, A & Stattin, P 2007, 'Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 - Data from the national prostate cancer register in Sweden', Scandinavian Journal of Urology and Nephrology, vol. 41, no. 6, pp. 456-477. https://doi.org/10.1080/00365590701673625

APA

CBE

Adolfsson J, Garmo H, Varenhorst E, Ahlgren G, Ahlstrand C, Andren O, Bill-Axelson A, Bratt O, Damber J-E, Hellstrom K, Hellstrom M, Holmberg E, Holmberg L, Hugosson J, Johansson J-E, Petterson B, Tornblom M, Widmark A, Stattin P. 2007. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 - Data from the national prostate cancer register in Sweden. Scandinavian Journal of Urology and Nephrology. 41(6):456-477. https://doi.org/10.1080/00365590701673625

MLA

Vancouver

Author

Adolfsson, Jan ; Garmo, Hans ; Varenhorst, Eberhard ; Ahlgren, Göran ; Ahlstrand, Christer ; Andren, Ove ; Bill-Axelson, Anna ; Bratt, Ola ; Damber, Jan-Erik ; Hellstrom, Karin ; Hellstrom, Magnus ; Holmberg, Erik ; Holmberg, Lars ; Hugosson, Jonas ; Johansson, Jan-Erik ; Petterson, Bill ; Tornblom, Magnus ; Widmark, Anders ; Stattin, Par. / Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 - Data from the national prostate cancer register in Sweden. In: Scandinavian Journal of Urology and Nephrology. 2007 ; Vol. 41, No. 6. pp. 456-477.

RIS

TY - JOUR

T1 - Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005 - Data from the national prostate cancer register in Sweden

AU - Adolfsson, Jan

AU - Garmo, Hans

AU - Varenhorst, Eberhard

AU - Ahlgren, Göran

AU - Ahlstrand, Christer

AU - Andren, Ove

AU - Bill-Axelson, Anna

AU - Bratt, Ola

AU - Damber, Jan-Erik

AU - Hellstrom, Karin

AU - Hellstrom, Magnus

AU - Holmberg, Erik

AU - Holmberg, Lars

AU - Hugosson, Jonas

AU - Johansson, Jan-Erik

AU - Petterson, Bill

AU - Tornblom, Magnus

AU - Widmark, Anders

AU - Stattin, Par

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Department of Urology, Lund (013077000), Pediatrics/Urology/Gynecology/Endocrinology (013240400)

PY - 2007

Y1 - 2007

N2 - Objective. The incidence of prostate cancer is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, tumor characteristics and treatment. Material and methods. Between 1996 and 2005, all new cases of adenocarcinoma of the prostate gland were intended to be registered in the National Prostate Cancer Register (NPCR). This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, tumor grade, tumor stage according to the TNM classification in force, serum prostate-specific antigen (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis. Results. In total, 72 028 patients were registered, comprising > 97% of all pertinent incident cases of prostate cancer in the Swedish Cancer Register (SCR). During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller tumors, a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of men diagnosed with distant metastases or with a PSA level of > 100 ng/ml at diagnosis and an increase in the proportion of tumors with Gleason score <= 6. Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c tumors were observed. Treatment with curative intent increased dramatically and treatment patterns varied according to geographical region. In men with localized tumors and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged >= 75 years than in those aged <75 years. Also, the pattern of endocrine treatment varied in different parts of Sweden. Conclusions. All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with early disease, predominantly tumors in category T1c. The patterns of diagnosis and treatment of prostate cancer vary considerably in different parts of Sweden. The NPCR continues to be an important source for research, epidemiological surveillance of the incidence, diagnosis and treatment of prostate cancer.

AB - Objective. The incidence of prostate cancer is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, tumor characteristics and treatment. Material and methods. Between 1996 and 2005, all new cases of adenocarcinoma of the prostate gland were intended to be registered in the National Prostate Cancer Register (NPCR). This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, tumor grade, tumor stage according to the TNM classification in force, serum prostate-specific antigen (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis. Results. In total, 72 028 patients were registered, comprising > 97% of all pertinent incident cases of prostate cancer in the Swedish Cancer Register (SCR). During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller tumors, a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of men diagnosed with distant metastases or with a PSA level of > 100 ng/ml at diagnosis and an increase in the proportion of tumors with Gleason score <= 6. Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c tumors were observed. Treatment with curative intent increased dramatically and treatment patterns varied according to geographical region. In men with localized tumors and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged >= 75 years than in those aged <75 years. Also, the pattern of endocrine treatment varied in different parts of Sweden. Conclusions. All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with early disease, predominantly tumors in category T1c. The patterns of diagnosis and treatment of prostate cancer vary considerably in different parts of Sweden. The NPCR continues to be an important source for research, epidemiological surveillance of the incidence, diagnosis and treatment of prostate cancer.

KW - register

KW - population-based

KW - prostate cancer

KW - epidemiology

KW - time trends

U2 - 10.1080/00365590701673625

DO - 10.1080/00365590701673625

M3 - Article

VL - 41

SP - 456

EP - 477

JO - Scandinavian Journal of Urology

JF - Scandinavian Journal of Urology

SN - 2168-1813

IS - 6

ER -